TuHURA Biosciences Inc. Watch

from S-8 40 pages 2 3 4 Kintara Therapeutics, Inc

from S-4/A 5 pages Tuhura Biosciences, Inc. Warrant Amendment Agreement

from S-4 10 pages Convertible Promissory Note

from S-4 7 pages Common Stock Purchase Warrant to Purchase Shares of Common Stock, Par Value $0.0001 Per Share, of Tuhura Biosciences, Inc

from S-4 11 pages Common Stock Purchase Warrant of Morphogenesis, Inc

from S-4 13 pages Common Stock Purchase Warrant of Morphogenesis, Inc

from S-4 13 pages Common Stock Purchase Warrant of Morphogenesis, Inc

from S-4 10 pages Warrant NO.A-[ ]

from S-4 15 pages Common Stock Purchase Warrant of Morphogenesis, Inc

from S-1/A 16 pages This Warrant to Purchase Shares of Common Stock (This “Warrant”) Certifies That, for Value Received, or Its Assigns (The “Holder”) Is Entitled, Upon the Terms and Subject to the Limitations on Exercise and the Conditions Hereinafter Set Forth, at Any Time on or After the Date Hereof (The “Initial Exercise Date”) and on or Prior to 5:00 P.M. (New York City Time) on [*], 2028 (The “Termination Date”) but Not Thereafter, to Subscribe for and Purchase From Kintara Therapeutics, Inc., a Nevada Corporation (The “Company”), Up to Shares of Common Stock, Par Value $0.001 Per Share (The “Common Stock”), of the Company (As Subject to Adjustment Hereunder, the “Warrant Shares”). the Purchase Price of One Warrant Share Under This Warrant Shall Be Equal to the Exercise Price, as Defined in Section 2(b). This Warrant Is Being Issued Pursuant to That Certain Placement Agent Agreement, Dated as of [*], 2023 by and Between the Company and A.G.P./ALLIANCE Global Partners. Section 1. Definitions. Capitalized Terms Used and Not Otherwise Defined Herein Shall Have the Meanings Set Forth in That Certain Securities Purchase Agreement (The “Purchase Agreement”), Dated [*], 2023, Among the Company and the Purchasers Signatory Thereto. Section 2. Exercise

from S-1/A 16 pages This Warrant to Purchase Shares of Common Stock (This “Warrant”) Certifies That, for Value Received, or Its Assigns (The “Holder”) Is Entitled, Upon the Terms and Subject to the Limitations on Exercise and the Conditions Hereinafter Set Forth, at Any Time on or After the Date Hereof (The “Initial Exercise Date”) and on or Prior to 5:00 P.M. (New York City Time) on [*], 2028 (The “Termination Date”) but Not Thereafter, to Subscribe for and Purchase From Kintara Therapeutics, Inc., a Nevada Corporation (The “Company”), Up to Shares of Common Stock, Par Value $0.001 Per Share (The “Common Stock”), of the Company (As Subject to Adjustment Hereunder, the “Warrant Shares”). the Purchase Price of One Warrant Share Under This Warrant Shall Be Equal to the Exercise Price, as Defined in Section 2(b). Section 1. Definitions. Capitalized Terms Used and Not Otherwise Defined Herein Shall Have the Meanings Set Forth in That Certain Securities Purchase Agreement (The “Purchase Agreement”), Dated [*], 2023, Among the Company and the Purchasers Signatory Thereto. Section 2. Exercise

from S-1/A 17 pages This Pre-Funded Warrant to Purchase Shares of Common Stock (This “Warrant”) Certifies That, for Value Received, or Its Assigns (The “Holder”) Is Entitled, Upon the Terms and Subject to the Limitations on Exercise and the Conditions Hereinafter Set Forth, at Any Time on or After the Date Hereof (The “Initial Exercise Date”) Until This Warrant Is Exercised in Full (The “Termination Date”) but Not Thereafter, to Subscribe for and Purchase From Kintara Therapeutics, Inc., a Nevada Corporation (The “Company”), Up to Shares of Common Stock, Par Value $0.001 Per Share (The “Common Stock”), of the Company (As Subject to Adjustment Hereunder, the “Warrant Shares”). the Purchase Price of One Warrant Share Under This Warrant Shall Be Equal to the Exercise Price, as Defined in Section 2(b). Section 1. Definitions. Capitalized Terms Used and Not Otherwise Defined Herein Shall Have the Meanings Set Forth in That Certain Securities Purchase Agreement (The “Purchase Agreement”), Dated [*], 2023, Among the Company and the Purchasers Signatory Thereto. Section 2. Exercise

from 8-K 19 pages Placement Agent Common Stock Purchase Warrant Kintara Therapeutics, Inc

from 8-K 19 pages Common Stock Purchase Warrant Kintara Therapeutics, Inc

from 8-K 18 pages Placement Agent Common Stock Purchase Warrant Kintara Therapeutics, Inc

from 8-K 18 pages Pre-Funded Common Stock Purchase Warrant Kintara Therapeutics, Inc

from 8-K 18 pages Common Stock Purchase Warrant Kintara Therapeutics, Inc

from S-3 55 pages Kintara Therapeutics, Inc., as Issuer and ●, as Trustee Indenture Dated as of ● Subordinated Debt Securities Cross Reference Sheet1 Between

from S-3 52 pages Kintara Therapeutics, Inc., as Issuer and ● , as Trustee Indenture Dated as of ● Senior Debt Securities Cross Reference Sheet1 Between

from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934